Resource Hub

Topic : News and Press Type : Press Release

UK HealthTech companies aiming to break into the US market are encouraged to apply now for the ABHI US Accelerator 2025.

With limited spaces and high demand, this programme offers an unparalleled gateway into the world’s largest healthcare market, giving UK medical device, diagnostic and digital health companies the support and connections they need to scale their businesses in the United States.

Now in its eighth year, the year-round programme features a series of trade missions across major life science hubs in the US, offering access to clinicians, senior leaders, and procurement teams at renowned hospital systems. 

New to 2025, the ABHI US Accelerator will expand its trade mission itinerary to include visits to key states, such as New Jersey and Arizona. Participants will also have the opportunity to visit other prominent regions, including Florida, Maryland, Washington D.C. and California. These missions offer access to leading US health institutions, including Rutgers University, Rowan University, Hackensack Meridian Health, Orlando Health, Baptist Health, Cedars-Sinai, and UCLA Health. 

Through these visits, UK companies will have direct channels to showcase their technologies to decision-makers across the US. 

Governor Phil Murphy of New Jersey, who recently met with ABHI and its member companies, said: “New Jersey is committed to fostering global partnerships that drive innovation and economic growth. Collaborating with ABHI and UK HealthTech leaders presents a unique opportunity to strengthen our state’s leadership in Life Sciences and HealthTech. Together, we are building a transatlantic pipeline of talent, technology, and ideas that will fuel advancements in healthcare and benefit communities on both sides of the Atlantic.”

The ABHI US Accelerator 2025 offers a robust suite of benefits tailored to help UK HealthTech companies accelerate their success in the competitive US market. Participants benefit from a powerful network of connections, with direct introductions to leading US hospital systems, academic health centres, insurers, group purchasing organisations (GPOs), investors, and economic development agencies. 

The programme has delivered significant value to UK HealthTech companies, with participants expecting to generate an average of $15 million in business over five years. The programme’s extensive network has also facilitated 70 clinical trials across US health systems, helping companies build crucial partnerships and gain exposure. 

Additionally, participants have reported securing contracts ranging from $250,000 to $60 million, showcasing the programme’s ability to drive success for companies looking to expand in the US healthcare market.

Paul Benton, Managing Director, International, ABHI, said: “Over the course of the year, our participating companies will engage with over 330 clinicians and senior executives at more than 35 hospitals and 20 academic health systems. This programme is about real connections – providing UK HealthTech innovators with a springboard to establish and grow their presence in the US.”

For ongoing learning and skill-building, the ABHI US Accelerator also includes a monthly webinar series covering essential topics such as regulation and market entry. This comprehensive series is designed to help companies understand and address critical success factors specific to the US healthcare ecosystem.

The programme will kick off in April with an in-person bootcamp workshop, offering expert-led sessions, networking opportunities, and valuable insights from industry leaders. This event will provide participants with the foundation they need for success in the US market, setting the stage for the year ahead.

Stephanie Juniat, Director of Commercial and Access Strategy, Cyted Health, commented: "The US Accelerator Programme gave us a unique opportunity to get exposure to and time with hard-to-access stakeholders across the US health ecosystem. The in-person element was invaluable, helping us better understand the variability in US healthcare and the challenges of launching into this complex market."

Interested companies are invited to join ABHI’s webinar on 3rd December to learn more about the opportunity. The session will feature Ruben Rathnasingham, Assistant Dean for Health Product Innovation at Dell Medical School, as well as alumni sharing their successful journey in the US market. Register here.

With spots filling quickly, interested companies should apply by 10th January 2025. This fee-for-service programme is open to companies at various stages – from early-stage innovators to SMEs with existing US operations. 

For more details and to apply, contact Sophie Green at sophie.green@abhi.org.uk.